New dipeptide mimetic of 2-nd loop of BDNF attenuates individual behavioral signs of opioid dependence in ratsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72020-11-010PREAI
New types of activity of the BDNF dipeptide mimetic: An psychostimulant, anti-opioid and anti-craving effects in opiate dependent rodentsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72019-12-011PREAI
Experimental study of endogenous dipeptide Cyclo-L-prolylglycine in aspects of opioid addiction and analgesia in rodentsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72019-01-014PREAI
ACTH4-10 analogue Semax and adamantane derivative hemantane produce significant reduction of withdrawal signs in morphine-dependent ratsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
The BDNF mimetic GSB-106 produces long-term analgesia and significant reduction of opiate withdrawal signs: comparison with dipeptide anxiolytic GB-115 effects in ratsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72016-10-013PREAI
Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transductionJOURNAL OF BIOMEDICAL SCIENCEIF12.12015-12-0848OAAI
New generation of anxiolytics for treatment of opiate-like addiction: advantages and possible clinical applicationEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72015-09-010PREAI
New peptide-origin anxiolytics, GB-115 and Selank, as possible tools in treatment of opiate addiction: an experimental studyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72014-10-010PREAI
A dipeptide analog of neurotensine (8-13) with mild analgesic activity significantly decreases opiate withdrawal signs in ratsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72013-10-010PREAI
New cholecyctokinin-4 retroanalog and dipeptide analog of neurotensin as opiate dependence correctors: an experimental studyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72011-04-013PREAI
Behavioural effects of cholecystokinin-4 dipeptide retro-analog in naive and morphine-dependent ratsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72005-01-012PREAI